AYUR.CN stock jumped 100.00% to C$0.01 during market hours on 06 Mar 2026 on the CNQ (Canada) as intraday trades pushed the price from the previous close of C$0.005. Volume remained modest at 12,030.00 shares versus a 50-day average near 152,341.00, so liquidity is a key watch. The move follows a recent earnings announcement and places Ayurcann Holdings Corp. under scrutiny for valuation, near-term catalysts and the reliability of short bursts in thinly traded small-cap healthcare names.

AYUR.CN stock: intraday move and volume

The immediate fact is a 100.00% one-day gain to C$0.01 on CNQ with 12,030.00 shares traded. That volume is 0.08x the stock’s average daily turnover, so the rally reflects a low-liquidity surge rather than broad market participation. Watch bid-ask spreads and order-book depth before sizing positions because thin trading can reverse quickly.

Earnings, fundamentals and valuation for AYUR.CN stock

Ayurcann reported an EPS of -0.03 and a negative trailing PE; TTM metrics show a PE around -0.44 and revenue per share C$0.16. Market cap is C$1,947,039.00 with 194,703,863.00 shares outstanding. Price-to-sales sits very low near 0.06, reflecting tiny market value against revenue, but book value per share remains negative, flagging structural weakness in equity.

Meyka AI grade and analyst context for AYUR.CN stock

Meyka AI rates AYUR.CN with a score out of 100: 73.65 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst signals. Note contrarian signals: an external company rating shows a C / Sell view dated 2026-03-04, underlining mixed opinions. Grades are model outputs and are not financial advice.

Technical picture and sector comparison for AYUR.CN stock

Technicals show RSI 55.49 and an ADX of 27.03, indicating a trending move but not extreme strength. AYUR.CN trades below its 200-day average (200-day approx C$0.03) and near the 50-day average (50-day approx C$0.01). In the Canadian Healthcare group, average PE is about 13.90, highlighting AYUR.CN’s atypical valuation given negative earnings and small market cap.

Catalysts, risks and trading strategy for AYUR.CN stock

Near-term catalysts include operational updates, bulk distillate sales volumes and any contract wins for post-harvest services. Key risks: thin liquidity, negative EPS, and tight cash runway indicated by current ratio near 0.61. For high-volume-mover traders, limit size, use limit orders, and place stop levels because sudden reversals are common in sub-penny names.

Price forecasts and realistic targets for AYUR.CN stock

Meyka AI’s forecast model projects a quarterly estimate near C$0.02 and a 12-month projection near C$0.01. Using those models, a short-term upside to C$0.02 implies +100.00% from the current C$0.01, while the 12-month C$0.01194 implies +19.42%. Forecasts are model-based projections and not guarantees; liquidity and corporate news will drive variance.

Final Thoughts

Key takeaways for AYUR.CN stock: the intraday 100.00% move to C$0.01 on 06 Mar 2026 is notable but driven by thin volume (12,030.00 vs avg 152,341.00). Fundamentals show negative EPS (-0.03) and a negative book value per share, while valuation ratios like price-to-sales (0.06) reflect the micro-cap scale rather than profitability. Meyka AI’s model gives a short-term target of C$0.02 (quarterly) and a 12-month model level near C$0.01194, implying a possible +100.00% and +19.42% move respectively from today’s price. The proprietary Meyka grade (B+, 73.65/100, BUY) balances recent growth metrics and forecasts against sector peers and should be weighed alongside an external C / Sell rating dated 2026-03-04. For traders focused on high-volume movers, position sizing, limit orders, and watchlists tied to company news, earnings updates and order-book liquidity are essential. Remember forecasts are model-based projections and not guarantees; do your own research and treat AYUR.CN as a high-risk micro-cap in Canada’s Healthcare segment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.